Insmed (INSM) – Analysts’ Recent Ratings Changes

Insmed (NASDAQ: INSM) recently received a number of ratings updates from brokerages and research firms:

  • 2/24/2023 – Insmed was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
  • 2/24/2023 – Insmed had its price target lowered by analysts at Cantor Fitzgerald from $49.00 to $46.00. They now have an “overweight” rating on the stock.
  • 2/24/2023 – Insmed had its “outperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $46.00 price target on the stock.
  • 2/24/2023 – Insmed had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
  • 1/20/2023 – Insmed had its price target lowered by analysts at Barclays PLC from $37.00 to $35.00. They now have an “overweight” rating on the stock.
  • 1/9/2023 – Insmed had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $44.00 to $39.00. They now have a “buy” rating on the stock.

Insmed Price Performance

NASDAQ:INSM opened at $20.09 on Tuesday. Insmed Incorporated has a 12-month low of $16.41 and a 12-month high of $28.94. The company’s 50-day moving average is $20.05 and its two-hundred day moving average is $20.90. The company has a current ratio of 6.69, a quick ratio of 6.33 and a debt-to-equity ratio of 13.13. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -5.15 and a beta of 1.56.

Insider Buying and Selling

In other Insmed news, COO Roger Adsett sold 3,194 shares of the stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $17.99, for a total value of $57,460.06. Following the completion of the sale, the chief operating officer now owns 135,487 shares of the company’s stock, valued at $2,437,411.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO Roger Adsett sold 3,194 shares of the firm’s stock in a transaction on Tuesday, January 10th. The stock was sold at an average price of $17.99, for a total transaction of $57,460.06. Following the transaction, the chief operating officer now directly owns 135,487 shares in the company, valued at $2,437,411.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael Alexander Smith sold 1,836 shares of the stock in a transaction on Tuesday, January 10th. The stock was sold at an average price of $17.93, for a total value of $32,919.48. Following the completion of the sale, the vice president now directly owns 54,332 shares in the company, valued at $974,172.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,592 shares of company stock valued at $518,005. 4.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of INSM. Norges Bank acquired a new position in shares of Insmed in the 4th quarter valued at $26,850,000. Emerald Advisers LLC acquired a new position in shares of Insmed in the 4th quarter valued at $19,878,000. GW&K Investment Management LLC boosted its position in shares of Insmed by 313.7% in the 4th quarter. GW&K Investment Management LLC now owns 995,777 shares of the biopharmaceutical company’s stock valued at $19,896,000 after purchasing an additional 755,076 shares during the period. Emerald Mutual Fund Advisers Trust acquired a new stake in Insmed during the 4th quarter worth about $14,928,000. Finally, Hudson Bay Capital Management LP boosted its position in Insmed by 390.2% during the 2nd quarter. Hudson Bay Capital Management LP now owns 784,300 shares of the biopharmaceutical company’s stock worth $15,466,000 after acquiring an additional 624,300 shares during the period. 92.83% of the stock is owned by institutional investors and hedge funds.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also

Receive News & Ratings for Insmed Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.